Bone Biologics Corporation (BBLG) Earnings History
Net Loss17 years of earnings data (2009–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Bone Biologics Corporation (BBLG) Earnings Overview
As of June 30, 2026, Bone Biologics Corporation (BBLG) reported trailing twelve-month net income of -$3M, reflecting +45.1% year-over-year growth. The company earned $-1.59 per diluted share over the past four quarters.
Looking at the long-term picture, BBLG's historical earnings data spans multiple years. The company achieved its highest annual net income of $0 in fiscal 2009.
Bone Biologics Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including XTNT ($2M net income, 3.7% margin), ATEC (-$125M net income, -18.8% margin), GMED ($587M net income, 18.3% margin), BBLG has comparable earnings metrics. Compare BBLG vs XTNT →
BBLG Earnings vs Peers
Earnings metrics vs comparable public companies
BBLG Historical Earnings Data (2009–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$3M | +24.4% | -$3M | $-2.65 | - | - |
| 2024 | -$4M | +54.1% | -$4M | $-4.83 | - | - |
| 2023 | -$9M | -502.8% | -$9M | $-34.01 | - | - |
| 2022 | -$1M | +7.8% | -$4M | $-31.20 | - | - |
| 2021 | -$2M | +11.7% | -$1M | $-37.35 | - | - |
| 2020 | -$2M | +46.7% | $-825,014 | $-35.68 | - | - |
| 2019 | -$3M | +22.7% | -$2M | $-66.97 | - | - |
| 2018 | -$4M | +37.2% | -$3M | $-3173.58 | - | - |
| 2017 | -$7M | +72.8% | -$3M | $-6480.00 | - | - |
| 2016 | -$26M | -86.5% | -$20M | $-24840.00 | - | - |
| 2015 | -$14M | -213.7% | -$12M | $-17640.00 | - | - |
| 2014 | -$4M | -308.9% | -$3M | $-10800.00 | - | - |
| 2013 | -$1M | -151228.7% | $-672,000 | $-37.48 | - | - |
| 2012 | $-715 | - | $-5,231 | $-49.11 | - | - |
| 2009 | $0 | - | $-3,000 | $0.00 | - | - |
Download Data
Export BBLG earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BBLG — Frequently Asked Questions
Quick answers to the most common questions about buying BBLG stock.
What is BBLG earnings per share (EPS)?
BBLG trailing twelve-month (TTM) diluted EPS is $-1.59, reflecting +45.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2009 to 2025 is available in the table on this page.
What is Bone Biologics Corporation's net income?
Bone Biologics Corporation (BBLG) trailing twelve-month net income is $-3M as of 2025. Earnings grew +45.1% year-over-year.
Is BBLG profitable?
BBLG is not currently profitable on a TTM basis, reporting a net loss of $-3M. Net margin is N/A. Investors should monitor for a return to profitability.
What is BBLG's earnings growth rate?
BBLG compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2009 to 2025.
What are BBLG's profit margins?
Bone Biologics Corporation net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -70.2%.
Is BBLG growing earnings?
Yes, BBLG earnings are accelerating — EPS growth of +45.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-3M. Earnings momentum is strengthening.
What was BBLG's best earnings year?
Bone Biologics Corporation's highest annual net income on record is $0.00, achieved in fiscal year 2009. Earnings history on this page spans 2009 to 2025 and includes all annual and quarterly figures.
What were BBLG's earnings last quarter?
BBLG's most recent reported quarter was Q1 2026. Net income was $-765988.00 with diluted EPS of $-0.43. For a full breakdown of all quarters, see the quarterly earnings table on this page.